Natera, Inc. - Common Stock (NQ:NTRA)

416.33 +5.98 (+1.46%)

Delayed Quote Updated: 11:15 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today ↗

February 06, 2025

Via Benzinga

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

February 03, 2025

From Natera, Inc.

Via Business Wire

Small- To Mid-Cap Biotech Trades Poised For Gains ↗

February 01, 2025

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...

Via Talk Markets

Topics ETFs Stocks / Equities

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

January 25, 2025

From Natera, Inc.

Via Business Wire

Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA). ↗

January 24, 2025

Exploring high growth characteristics of NATERA INC (NASDAQ:NTRA). A fundamental and technical analysis of (NASDAQ:NTRA).

Via Chartmill

Looking Into Natera's Recent Short Interest ↗

January 20, 2025

Via Benzinga

The Analyst Verdict: Natera In The Eyes Of 14 Experts ↗

January 10, 2025

Via Benzinga

Natera to Present New Data at the 2025 ASCO GI Symposium

January 21, 2025

From Natera, Inc.

Via Business Wire

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone ↗

January 21, 2025

The company is working to expand the uses and reimbursement for its blood-based tests for cancer.

Via Investor's Business Daily

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,...

Via Benzinga

The End Of The 60/40 Portfolio ↗

January 17, 2025

Since bonds don't protect against stock declines, it's time for a different approach.

Via Benzinga

Topics Bonds

Why NASDAQ:NTRA qualifies as a high growth stock. ↗

January 03, 2025

Should you consider NATERA INC (NASDAQ:NTRA) for high growth investing?

Via Chartmill

Exploring NASDAQ:NTRA's high growth characteristics. ↗

December 13, 2024

Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA).

Via Chartmill

Looking Into Natera's Recent Short Interest ↗

December 02, 2024

Via Benzinga

Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday ↗

January 17, 2025

Via Benzinga

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

January 17, 2025

From Natera, Inc.

Via Business Wire

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

January 15, 2025

From Natera, Inc.

Via Business Wire

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

January 12, 2025

From Natera, Inc.

Via Business Wire

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings ↗

January 09, 2025

Via The Motley Fool

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 07, 2025

From Natera, Inc.

Via Business Wire

Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next ↗

December 24, 2024

Druckenmiller's Duquesne Family Office sold Nvidia and Palantir stocks while increasing stake in Teva Pharmaceutical, signaling a shift in investment focus.

Via Benzinga

Topics Artificial Intelligence

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings ↗

December 21, 2024

Via The Motley Fool

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252% ↗

December 20, 2024

Billionaire Stanley Druckenmiller's latest large wager on biotech company Natera Inc has paid off, with his stake now exceeding $575 million.

Via Benzinga

Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics

December 17, 2024

From Natera, Inc.

Via Business Wire

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

December 12, 2024

From Natera, Inc.

Via Business Wire

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

December 09, 2024

From Natera, Inc.

Via Business Wire

Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology

December 02, 2024

From Natera, Inc.

Via Business Wire

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

November 27, 2024

From Natera, Inc.

Via Business Wire

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

November 25, 2024

From Natera, Inc.

Via Business Wire

Natera Issues Statement on Guardant Health Litigation

November 25, 2024

From Natera, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.